BACKGROUND: Excess use of intravenous fluid can increase post-operative complications. We examined the influence of intra-operative crystalloid (IOC) administration on complications following pancreaticodudenectomy (PD) for pancreatic adenocarcinoma. METHODS: We categorized 188 patients who underwent PD for adenocarcinoma (1990-2009) into two groups: Group I received <6,000 ml and Group II received ≥6,000 ml IOC. Differences between groups in length of stay, overall morbidity, and 30-day mortality were evaluated. RESULTS: There were 86 patients in Group I and 102 in Group II. Group I patients were older and with higher percentage of women, but similar in regards to performance status, ASA score, underlying comorbidities, and administration of neo-adjuvant treatment. Group II patients had longer operations, increased blood loss, and higher rates of intra-operative blood transfusions. There were two post-operative deaths, both in the Group II (P = 0.5). Post-operative overall morbidity was 45.7%, without differences between the two groups (44.2% vs. 47.1%, P = 0.7). Likewise, length of post-operative stay was similar in both groups (13.8 days vs. 14.5 days, P = 0.5). CONCLUSIONS: The volume of IOC increased with duration of surgery, intra-operative blood losses, and intra-operative blood transfusion, but did not correlate with post-operative morbidity.
BACKGROUND: Excess use of intravenous fluid can increase post-operative complications. We examined the influence of intra-operative crystalloid (IOC) administration on complications following pancreaticodudenectomy (PD) for pancreatic adenocarcinoma. METHODS: We categorized 188 patients who underwent PD for adenocarcinoma (1990-2009) into two groups: Group I received <6,000 ml and Group II received ≥6,000 ml IOC. Differences between groups in length of stay, overall morbidity, and 30-day mortality were evaluated. RESULTS: There were 86 patients in Group I and 102 in Group II. Group I patients were older and with higher percentage of women, but similar in regards to performance status, ASA score, underlying comorbidities, and administration of neo-adjuvant treatment. Group II patients had longer operations, increased blood loss, and higher rates of intra-operative blood transfusions. There were two post-operative deaths, both in the Group II (P = 0.5). Post-operative overall morbidity was 45.7%, without differences between the two groups (44.2% vs. 47.1%, P = 0.7). Likewise, length of post-operative stay was similar in both groups (13.8 days vs. 14.5 days, P = 0.5). CONCLUSIONS: The volume of IOC increased with duration of surgery, intra-operative blood losses, and intra-operative blood transfusion, but did not correlate with post-operative morbidity.
Authors: Florence Grant; Murray F Brennan; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Michael D'Angelica; Mary E Fischer; Mithat Gonen; Hao Zhang; William R Jarnagin Journal: Ann Surg Date: 2016-10 Impact factor: 12.969
Authors: Mikaela L Garland; Hamish S Mace; Andrew D MacCormick; Stuart A McCluskey; Nicholas J Lightfoot Journal: J Gastrointest Surg Date: 2019-01-22 Impact factor: 3.452
Authors: Mark A Healy; Robert W Krell; Zaid M Abdelsattar; Laurence E McCahill; David Kwon; Timothy L Frankel; Samantha Hendren; Darrell A Campbell; Sandra L Wong Journal: Ann Surg Oncol Date: 2015-03-28 Impact factor: 5.344
Authors: Oliver S Eng; Julie Goswami; Dirk Moore; Chunxia Chen; Christopher J Gannon; David A August; Darren R Carpizo Journal: J Surg Oncol Date: 2013-08-01 Impact factor: 3.454
Authors: Leah K Winer; Vikrom K Dhar; Koffi Wima; Tiffany C Lee; Mackenzie C Morris; Shimul A Shah; Syed A Ahmad; Sameer H Patel Journal: J Gastrointest Surg Date: 2018-06-04 Impact factor: 3.452